Last updated on April 16, 2014 at 6:04 EDT

Global Biosimulation Market worth $1.2 Billion by 2017

October 12, 2012

DALLAS, October 12, 2012 /PRNewswire/ –

The report “Global Biosimulation Market (Insilico Technology Markets for Drug
Development) (2012 – 2017)” defines and segments the global biosimulation market with
analysis of forecasting of the global revenue and applications revenue for biosimulation.
It also identifies driving and restraining factors for the global biosimulation market
with analysis of trends, opportunities, challenges, strengths, weakness and threats. The
market is segmented and revenue is forecasted on the basis of major region such as North
America, Europe, Asia and Rest of the World. Market is segmented and revenues are
forecasted on the basis of application and region.

Browse more than 51 market data tables/figures spread through 130 pages and in-depth
TOC on “Global Biosimulation Market (Insilico Technology Markets for Drug Development)
(2012 – 2017)”.


Early buyers will receive 10% customization on reports.

Biosimulation is one the fastest growing technology applied in drug discovery and
development process. The decline in output and increase in cost in R&D for new drug
discovery and development is a major growth factor for the biosimulation. With many drug
candidates failing in the late development stages, pharmaceutical companies are under
pressure to reduce cost spent by focusing only on specific experiments, Biosimulation aids
in focusing on potentially safe drug candidate and developing it into a successful drug.

The key growth area is application of Pharmacokinetic/pharmacodynamic (PKPD) modeling
in pre clinical development it is the most widely used model in drug development process
which is driving the growth of biosimulation.

Modelling and simulation are widely used across the drug development process in large
and small pharmaceutical companies. Pharmaceutical companies realize that integrating
existing knowledge and using quantitative simulation methods offer significant savings in
time, money and material over expensive in vitro and in vivo studies. The global market
for biosimulation in terms of revenue was estimated to be worth $432.0 million in 2011 and
is expected to reach $1.2 billion by 2017, growing at a CAGR of 18.50% from 2012 to 2017.

About MarketsandMarkets

MarketsandMarkets is a global market research and consulting company based in the U.S.
We publish strategically analyzed market research reports and serve as a business
intelligence partner to Fortune 500 companies across the world. MarketsandMarkets also
provides multi-client reports, company profiles, databases, and custom research services.

MarketsandMarkets covers thirteen industry verticals; including advanced materials,
automotives and transportation, banking and financial services, biotechnology, chemicals,
consumer goods, energy and power, food and beverages, industrial automation, medical
devices, pharmaceuticals [
http://www.marketsandmarkets.com/pharmaceutical-market-research-3.html ],
semiconductor and electronics, and Telecommunications and IT.

We at MarketsandMarkets are inspired to help our clients grow by providing apt
business insight with our huge market intelligence repository. To know more about us and
our reports, please visit our website http://www.marketsandmarkets.com.

        Mr. Rohan
        North - Dominion Plaza,
        17304 Preston Road,
        Suite 800, Dallas, TX 75252
        Tel: +1-888-6006-441
        Email: sales@marketsandmarkets.com
        MarketsandMarkets Blog @ http://www.marketsandmarketsblog.com




SOURCE MarketsandMarkets

Source: PR Newswire